HealthDay - Diet Drug Rimonabant Tied to Depression, Anxiety
People who take the weight-loss drug rimonabant may face heightened risks for severe depression and anxiety, Danish researchers report.
The finding follows a recommendation by a U.S. Food and Drug Administration panel in June that the agency not approve the diet drug because of continuing concerns about increased risks for suicidal thoughts among some users. Previously, the FDA rejected the drug as an aid to help people quit smoking.
“Up to this point in time, there has been controversy over the rates and severity of psychiatric adverse effects with rimonabant,” noted Dr. Philip Mitchell, head of the School of Psychiatry at the University of New South Wales in Sydney, Australia, and co-author of an editorial that accompanies the study.
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
FDA Shouldn’t Approve Diet Drug, Panel Says
Pill could help obesity and smoking.(News)(Brief Article)
Shares in Sanofi fall after anti-obesity drug setback
This is the first review to examine rates of severe psychiatric symptoms with rimonabant (Acomplia), symptoms severe enough that patients discontinue treatment, Mitchell said.
The report is published …
Read the full article with a Free Trial at MyWire.
